NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Telix Pharmaceuticals Limited (TLX) Stock Analysis

Telix Pharmaceuticals Limited (TLX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TLX

$11.94

+$0.20 (+1.70%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TLX with… →

TLX Key Statistics

As of Sep 4, 2026
Trading
Open
$11.84
Previous Close
$11.74
Day's Range
11.84–11.95
52-Week Range
6.28–12.48
Volume
141.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.60
Valuation
Market Cap
$4.06B
P/E Ratio
119.40
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
82.11
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.55
EPS (ttm)Profit attributable to each share over the last twelve months.
0.10
Financials (FY)
Revenue (FY)
$803.79M+55.61%
Net Income (FY)
−$7.13M−121.15%
Profit marginThe share of revenue left as profit after all costs and taxes.
3.76%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
339.78M
1-Year Return
+31.50%
Dividend and dates
Avg Volume
156.52K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TLX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+59.41%
2025−51.36%
2024 (partial year)+1.65%

As of September 4, 2026.

TLX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$803.79M−$7.13M−0.9%
2024$516.55M$33.69M6.5%
2023$332.98M$4.21M1.3%
2022$108.91M−$104.08M−95.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$803.79M$426.44M$18.05M−$7.13M−0.9%
2024$516.55M$336.16M$55.58M$33.69M6.5%
2023$332.98M$209.53M$34.97M$4.21M1.3%
2022$108.91M$64.58M−$50.48M−$104.08M−95.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TLX Valuation vs Biotechnology Median

Median of 656 stocks
MetricTLXBiotechnology medianvs median
P/E119.4012.579.5x the median
P/S ratio4.5515.260.3x the median
Profit margin3.76%0.00%3.8 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Telix Pharmaceuticals Limited (TLX) carries a market capitalisation of $4.06B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 1,120.

TLX last closed at $11.94 on September 4, 2026. That is +$0.20 (+1.70%) against the previous close. The 52-week range on file runs from $6.28 to $12.48. The latest close sits 90.13% above that 52-week low.

Financial Health

In fiscal 2025, Telix Pharmaceuticals Limited reported revenue of $803.79M. Against the prior fiscal year total of $516.55M, that is a change of +55.61%. The same year closed with a net loss of $7.13M. Profit margin runs at 3.76%. That is 3.8 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 0.1.

Across the 4 fiscal years on file, revenue moves from $108.91M in 2022 to $803.79M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 119.4 times earnings. That is 9.5 times the Biotechnology median of 12.57. On forward earnings the ratio is 82.11. Measured against sales, the shares trade at 4.55 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +31.50%. The stored price history starts on November 14, 2024, and the total return since then is −21.19%. The reported beta is 0.6. Annualized volatility over the trailing 1 year is 54.44%.

Growth & Income

No dividend is on file for TLX.

2026 is still running; the price is +59.41% year to date. The record holds one complete calendar year, 2025, which returned −51.36%.

Peer Comparison

Telix Pharmaceuticals Limited (TLX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Telix Pharmaceuticals Limited TLX $4.06B 119.4
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Telix Pharmaceuticals Limited trades at a P/E of 119.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Visit website →